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mostly distant metastasis, most patients with N2 disease
require a multimodal strategy, and recent efforts to
improve the outcome of the disease have focused on
this strategy.4-13 Some of the trials have shown promis-
ing results. In particular, induction chemotherapy fol-
lowed by surgical resection was reported to be superior
to surgery alone in at least 2 phase III clinical trials.8,13
Concurrent chemoradiation either alone or given as
neoadjuvant therapy before surgical resection has also
been reported to be promising and cures about 30% of
N2 disease.10,14
On the other hand, the reported prognosis of N2 dis-
ease varies tremendously. In non–small cell lung can-
cer, N2 disease is known to be a heterogeneous subcat-
egory, and some authors1,3,15-18 have suggested several
significant prognostic factors among surgically resected
N2 disease. However, controversy still remains as to
T he prognosis of surgically resected non–small celllung cancer with metastasis to ipsilateral mediasti-
nal lymph node (N2 disease) is poor, although highly
selected patients with N2 disease achieve a 5-year sur-
vival.1-3 Because the failure pattern of N2 disease is
Background: Clinical trials dealing with multimodal strategy for N2
non–small cell lung cancer are now being watched with keen interest,
and the feasibility of this strategy is to be confirmed. N2 lung cancer,
however, is composed of several subgroups with different prognoses.
The prognostic factors still remain controversial. Methods: Between
January 1986 and July 1997, 222 patients with lung cancer underwent
surgical intervention at our institute; these patients were eventually
given a diagnosis of metastasis to ipsilateral mediastinal lymph nodes.
All patients underwent mediastinal lymph node dissection or sampling.
Sixteen clinicopathologic factors were investigated by univariable and
multivariable analyses to identify significant prognostic factors among
resected N2 disease. Clinical N status was evaluated by computed tomo-
graphic scan. Results: The overall 5-year survival was 27%. Multi-
variable analyses among overall patients revealed 4 significant prognos-
tic factors (P < .05): clinical N2 status, incomplete resection, larger
tumor size, and multiple diseased N2 nodes. Based on the result, 32
patients with both clinical N2 status and pathologic multiple N2 nodes
showed a 5-year survival of 5%, whereas 76 patients with neither of the
factors showed a 5-year survival of 57% (P < .001). Conclusion: The prog-
nosis of surgically resected N2 disease varies tremendously according to
the 4 significant prognostic factors. These factors should be clearly
described in reporting clinical trials on N2 lung cancer. Clinical N sta-
tus evaluated by computed tomographic scan should be 1 criterion to
perform a clinical trial for N2 disease among a homogeneous population
with respect to prognosis. (J Thorac Cardiovasc Surg 1999;118:145-53)
Kenji Suzuki, MD
Kanji Nagai, MD
Junji Yoshida, MD
Mitsuyo Nishimura, MD
Kenro Takahashi, MD
Yutaka Nishiwaki, MD
From the Division of Thoracic Oncology, National Cancer Center
Hospital East, Chiba, Japan.
Supported in part by a Grant-in-Aid for Cancer Research from the
Ministry of Health and Welfare.
Received for publication Dec 1, 1998; revisions requested Feb 11,
1999; revisions received March 1, 1999; accepted for publication
March 15, 1999.
Address for reprints: Kenji Suzuki, MD, Division of Thoracic
Oncology, National Cancer Center Hospital East, 6-5-1,
Kashiwanoha, Kashiwa, Chiba, 277 Japan.
Copyright © 1999 by Mosby, Inc.
0022-5223/99 $8.00 + 0 12/1/98582
145
GENERAL THORACIC SURGERY
THE PROGNOSIS OF SURGICALLY RESECTED N2 NON–SMALL CELL LUNG CANCER: 
THE IMPORTANCE OF CLINICAL N STATUS
which prognostic factors have greater impact on the
survival of N2 non–small cell lung cancer. This contro-
versy is probably related to criteria such as patient
selection, the limited number of patients with analyzed
disease, and inappropriate intraoperative staging (that
is, mediastinal lymph node dissection). Although clini-
cally evident N2 disease could be one of the most sig-
nificant prognostic factors,3,19 some authors17,20 report-
ed different conclusions. Thus N2 non–small cell lung
cancer is composed of a heterogeneous population in
terms of prognosis. Therefore it is possible that even
phase III clinical trials dealing with N2 disease could
draw erroneous conclusions because of patient selec-
tion bias. Although many clinical trials investigating
multimodal strategy for N2 disease have been reported
to be promising, a favorable outcome could be based on
this selection bias. Unless the enrolled cases were suf-
ficiently numerous, the outcome of the trial could be
influenced by the incidental bias of the prognostic fac-
tors among patients in each arm of the phase III trial.
In this retrospective study, we attempted to clarify
several clinicopathologic prognostic factors and define
homogeneous subgroups among patients with N2 dis-
ease to make it easier to correctly interpret clinical tri-
als for this entity. Especially we will attempt to evalu-
ate the importance of clinical N status in interpreting
the outcome of N2 disease and other significant prog-
nostic factors, which should be clearly described in
clinical trial reports.
Patients and methods
Selected patients. Between January 1986 and July 1997,
1156 patients with lung cancer underwent surgical interven-
tion at our institute, and 242 (21%) were eventually given a
diagnosis of metastasis to ipsilateral mediastinal lymph
nodes (N2 disease). Among them, 222 patients with lung
cancer, who underwent major lung resection and mediastinal
lymph node sampling, were selected to be investigated in
this study because possible stage migration could be
observed in the other 20 patients. One hundred forty were
men and 82 were women. Their ages ranged from 23 to 83
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Table I. Characteristics of patients with surgically
resected N2 non–small cell lung cancer
Variables Clinical N0-1 Clinical N2 P value*
Total (n) 135 87 —
Age (y)
<60 55 34 .81
‡ 60 80 53
Gender
Male 76 64 .009†
Female 59 23
CEA
<5.0 ng/mL 51 18 .11
‡ 5.0 ng/mL 59 36
Clinical T status 
cT1-2 121 52 <.001†
cT3-4 14 34
Location of the main tumor‡
RUL/RML 48 26 .69
RLL 32 18
LUL 38 30
LLL 17 12
Histologic condition
Adenocarcinoma 97 46 .004†
Squamous cell 27 34
Adenosquamous 9 5
Large cell 2 2
Tumor size
≤2.0 cm 14 8 .77
>2.0 cm 121 79
Pathologic T status
T1 38 16 .002†
T2 58 23
T3 16 22
T4 23 25
Table I. Continued
Variables Clinical N0-1 Clinical N2 P value*
Pathologic stage‡
Stage IIIA 111 61 .019†
Stage IIIB 21 23
Stage IV 1 3
Pleural involvement
P0 61 29 .08
P1-3 74 58
Vascular invasion
Positive 101 78 .008†
Negative 33 9
Intrapulmonary metastasis
Positive 16 16 .18
Negative 117 70
Metastatic N2 stations
Single 83 37 .01†
Multiple 51 47
Metastatic N2 nodes
1 32 11 .04†
2 or more 103 76
Procedure of operation§
Pneumonectomy 9 24 <.001†
Lobectomy 126 63
Curativity
CompleteII 111 56 .003†
Incomplete 24 31
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL,
left upper lobe; LLL, left lower lobe.
*P value in the c 2 test.
†Considered to be statistically significant.
‡
c
2 Test was performed between stage IIIA vs stage IIIB or IV.
§Dichotomized: lobectomy, bilobectomy vs pneumonectomy.
IIComplete resection means no diseased surgical resection margin and no
highest mediastinal lymph node involvement.
years, with a median of 63 years. Pretreatment staging con-
sisted of clinical history, physical examination, and periph-
eral blood analyses, including arterial blood gas analyses,
liver function test, renal function test, and serum carcinoem-
bryonic antigen (CEA) in most patients. All patients under-
went thoracic and brain computed tomographic (CT) scan
preoperatively. The CT experiments were performed on an
X-vision/SP (Toshiba, Tokyo, Japan), and 10-mm thick con-
tiguous sections were used to evaluate N2 status. The clini-
cal diagnosis of nodal involvement was determined by diag-
nostic radiologists and based on the CT findings (that is,
mediastinal or hilar lymph nodes 1.0 cm or larger in the
shortest axis were diagnosed as metastatic).21 Clinical N2
disease was diagnosed in 201 patients, and among them 95
patients (47%) were actually diagnosed to have pathologic
N2 disease. Abdominal CT scan or ultrasonography was per-
formed in all patients. Bone scintigraphy was also performed
in all patients. Mediastinoscopy was performed in 12
patients, with positive results in 10 patients and negative
results in 2 patients. All 12 patients had been enrolled in a
previously conducted phase III clinical trial, in which preop-
erative chemotherapy versus surgical resection alone was
investigated. The indications for mediastinoscopy included
enlarged mediastinal lymph nodes on CT scan based on the
size criteria described earlier. Because the basic strategy for
resectable clinical N2 disease, however, had been primary
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Table II. The 5-year survival of surgically resected N2 non–small cell lung cancer according to the metastatic
mediastinal lymph node stations* and the primary tumor location (%)
Regional nodal stations
TOTAL Superior Inferior Aortic Superior aortic
No. 1-9 No. 1-4 No. 7-9 No. 5-6 No. 1-6
Tumor location
Upper lobe 31 (n = 142) 25 (n = 92) 22 (n = 24) — 36† (n = 130)
Lower lobe 20 (n = 79) 17† (n = 43) 0† (n = 46) — 20 (n = 45)
RUL/RML 27 (n = 74) 28 (n = 69) 33 (n = 11) — —
RLL 14 (n = 50) 18 (n = 30) 0† (n = 29) — —
LUL 35 (n = 68) 18 (n = 23) 13 (n = 13) 40 (n = 54) 37 (n = 61)
LLL 32 (n = 29) 15 (n = 13) 23 (n = 17) 15 (n = 10) 22 (n = 15)
TOTAL 27 (n = 222) 23 (n = 135) 12 (n = 70) 33 (n = 64) 29 (n = 175)
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
*Regional nodal stations according to the lymph node map by Naruke and colleagues24.
†Considered to be statistically significant (log-rank test, P < .05).
Fig 1. Survival curve for patients with surgically resected N2 stage non–small cell lung cancer. The bar indicates
95% CI.
surgical resection in our institute, only patients enrolled in
the clinical trial underwent mediastinoscopy.
Histologic typing was determined according to the World
Health Organization classification.22 All resected specimens
were formalin fixed and sliced at 5- to 10-mm intervals.
Primary lung neoplasms and nodules were evaluated micro-
scopically by conventional hematoxylin and eosin stain.
Histologic typing of resected lung cancer resulted in 143 ade-
nocarcinomas, 61 squamous cell carcinomas, 4 large cell car-
cinomas, and 14 adenosquamous carcinomas. Two small cell
carcinomas and 3 bronchial carcinoids were excluded from
this study. The stage of the disease was based on the TNM
classification of the International Union Against Cancer, fifth
edition23; cases with separate tumor nodules in the same lobe
were designated as T4, and separate tumor nodules in differ-
ent lobes as M1. Pathologic examination revealed 55 T1 cases
(24%), 81 T2 cases (36%), 38 T3 cases (17%), and 48 T4
cases (22%). A total of 173 patients were classified as having
pathologic stage IIIA disease; 45 patients, as stage IIIB dis-
ease; and 4 patients, as stage IV disease. Patients who had
undergone at least mediastinal lymph node sampling were
included. Complete mediastinal lymph node dissection was
performed in 206 patients (93%), and dissected lymph nodes
were described according to the lymph node map for lung
cancer proposed by Naruke and associates.24 All resected
lymph nodes were formalin fixed and examined microscopi-
cally by standard hematoxylin and eosin stain. The number of
dissected lymph nodes ranged from 4 to 86, with an average
of 29 dissected lymph nodes. The number of staff surgeons is
4, and they generally perform mediastinal lymph node dis-
section in the same manner as described by Naruke and asso-
ciates.24
Investigated clinicopathologic features. The medical
record of each patient was examined for age, gender, pack-
years of smoking, preoperative serum CEA level (‡ 5.0 vs
<5.0 ng/mL), the location of the primary tumor, clinical T sta-
tus (cT1-2 vs cT3-4), clinical N status (cN0-1 vs cN2), histo-
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Table III. Relationship between clinicopathologic
factors and 5-year survival in surgically resected
pathologic N2 stage non–small cell lung cancer
5-Year 
Prognostic factors N survival (%) c 2 P value*
Total 222 27 — —
Age (y)
<60 89 27 <0.01 .99
‡ 60 133 26
Gender 
Male 140 24 3.36 .067
Female 82 32
Smoking status
0≤PY <40 128 31 1.88 .17
40≤PY 85 15
CEA
<5.0 ng/mL 76 34 1.46 .23
‡ 5.0 ng/mL 88 17
Clinical T status
cT1-2 173 31 6.43 .011†
cT3-4 48 13
Clinical N status
cN0-1 135 43 37.3 <.001†
cN2 87 7
Histologic condition
Adenocarcinoma 143 31 0.27 .60
Others 79 21
Differentiation
Well 56 31 0.30 .58
Moderate or poor 154 29
Tumor size
≤2.0 cm 22 47 4.71 .030†
>2.0 cm 200 25
Chemotherapy
Performed 44 27 0.13 .72
Not performed 178 24
Table III. Continued
5-Year 
Prognostic factors N survival (%) c 2 P value*
Pathologic T status
pT1-3 174 31 7.87 .005†
pT4 48 14
Pathologic stage
Stage IIIA 173 31 9.07 .003†
Stage IIIB or IV 49 14
Pleural involvement
P0 90 30† 4.29 .038†
P1-3 132 25
Vascular invasion
Positive 179 25 2.95 .086
Negative 42 36
Intrapulmonary metastasis
Positive 32 5 11.15 <.001†
Negative 190 31
Metastatic N2 stations
Single 120 35 4.18 .041†
Multiple 98 19
Metastatic N2 nodes
1 43 47 6.82 .009†
2 or more 179 22
Procedure of operation‡
Pneumonectomy 33 13 8.11 .004†
Lobectomy 189 31
Curativity§
Complete 167 36 16.37 <.001†
Incomplete 55 0
Radiation therapy
Performed 20 0 3.95 .047†
Not performed 202 30
cN0-1, Patients with clinical N0-1 status; cN2, patients with clinical N2 sta-
tus. PY, pack-year smoking.
*P value in the log rank test.
†Considered to be statistically significant.‡Dichotomized: lobectomy, bilobec-
tomy vs pneumonectomy.
§Complete resection means no diseased surgical resection margin and no high-
est mediastinal lymph node involvement.
logic evidence (adenocarcinoma vs others), maximum tumor
dimension (centimeters), pathologic T status, pathologic
stage, differentiation of tumor (well vs moderate or poor),
pleural involvement (P0 vs P1-3), vascular invasion (positive
vs negative), intrapulmonary metastasis (present vs absent),
number of metastatic mediastinal lymph node stations (single
vs multiple), number of metastatic mediastinal lymph nodes
(1 vs 2 or more), procedure of operation (pneumonectomy vs
lobectomy or limited surgery), curativity of surgical resection
(complete vs incomplete), adjuvant radiation (performed vs
not performed), and adjuvant chemotherapy (performed vs
not performed). Pleural involvement was classified as P0, P1,
P2, and P3: P0 included tumor with no pleural involvement
or reaching the visceral pleura but not extending beyond its
elastic pleural layer; P1 included tumor reaching the visceral
pleural elastic layer but not exposed on the pleural surface;
P2 included tumor exposed on the pleural surface; and P3
included tumor invading the parietal pleura or chest wall.25
Vascular invasion indicated tumor cells identifiable in the
blood vessel lumen. Pulmonary metastasis was defined as an
independent mass isolated from the primary malignancy with
identical histopathologic features as the primary tumor.
Curativity was defined in the following manner: Complete
resection indicates no diseased surgical resection margin and
no diseased highest mediastinal lymph node, and incomplete
resection means the presence of cancer cells at surgical mar-
gin histologically or the presence of involved highest medi-
astinal lymph node.
Statistical analyses. The median follow-up period for 99
patients alive was 44 months. The length of survival was
defined as the interval in months between the day of surgical
resection of lung carcinoma and the date of death from any
cause or last follow-up. The survivals were calculated by the
Kaplan-Meier method,26 and univariate analyses were per-
formed by means of the log rank test. Multivariable analyses
were performed by means of Cox’s proportional hazards
model on StatView J 4.11 (Abacus Concepts, Inc, Berkeley,
Calif) with a Power Macintosh 8100/100AV (Apple
Computer, Inc, Cupertino, Calif).27 Forward and backward
stepwise procedures were used to determine the combination
of factors that were essential in predicting prognosis. If vari-
ables could be used as continuous variables, continuous vari-
ables were used instead of dichotomous variables in multi-
variate analyses. The 0.10 level of significance was the
significance level used for entering or removing a covariable
from the model. The c 2 test or Fisher’s exact test was used to
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 1
Suzuki et al   149
Fig 2. Survival for patients with surgically resected N2 state non–small cell lung cancer were compared on the
basis of clinical N status. A statistically significant difference was observed between outcomes of clinical N0-1 and
N2 disease (log-rank test, P < .001). cN0-1, Patients with clinical N0-1 status; cN2, patients with clinical N2 status.
Table IV. Multivariate analyses of prognostic factors
in surgically resected pathologic N2 non–small cell
lung cancer*
Variables OR 95% CI P value
Clinical N status
cN0-1 vs cN2 2.60 1.79-3.77 <.001
Tumor size (cm)† 1.22 1.12-1.32 <.001
Metastatic N2 nodes† 1.08 1.12-1.32 <.001
Curativity‡
Complete vs incomplete 1.58 1.06-2.33 .023
cN0-1, Patients with clinical N0-1 status; cN2, patients with clinical N2 status.
*Final models with all significant independent variables are shown.
†Entered as a continuous variable into the multiple variable analysis.
‡Complete resection means no diseased surgical resection margin and no high-
est mediastinal lymph node involvement.
compare several prognostic factors among subgroups in N2
lung cancer.
Results
Among 222 surgically resected N2 non–small cell
lung cancers, 135 (61%) were clinical N0-1 status
based on the CT scan; 87 (39%) were clinical N2 sta-
tus. Clinicopathologic features were compared between
clinical N0-1 and N2 disease (Table I). Male gender,
clinical T3-4 status, squamous cell histologic condi-
tion, pathologic T status, vascular invasion, the number
of stations of diseased N2 nodes, the number of N2
nodes, pneumonectomy, and curativity were signifi-
cantly associated with clinical N status (P < .05).
Metastatic mediastinal lymph node status was inves-
tigated in detail. The prognosis of N2 disease according
to the site of diseased N2 nodes is shown in Table II.
The overall 5-year survival was 27% (n = 222; Fig 1).
The prognosis of patients with diseased inferior N2
nodes (n = 70) was significantly worse than the others
(5-year survival, 12%; P < .05). As for tumors located
in the upper lobes, superior aortic N2 (n = 130) disease
had a significantly better prognosis (5-year survival,
36%; P < .05). As to tumors located in the lower lobes,
no patients with inferior diseased N2 nodes survived 5
years. In contrast, when the primary tumor was located
in the left upper lobe, patients with N2 nodes in the aor-
tic region had a 5-year survival of 40%, although this
was not statistically significant.
The prognosis of surgically resected N2 non–small
cell lung cancer was investigated according to several
clinicopathologic prognostic factors (Table III).
Significant differences in outcome were observed in
relation to several clinicopathologic features. The 5-
year survival of 87 patients with clinical N2 status was
only 7%, although the survival of 135 patients with
clinical N0-1 status was 43% (P < .001; Fig 2).
Multivariable analyses with Cox’s proportional hazard
model disclosed 4 independent prognostic factors
(Table IV): clinical N2 status, larger tumor size, multi-
ple diseased N2 nodes, and curativity. On the basis of
the results, we could identify a subgroup with poorer
prognosis among resected N2 disease (Table V).
Patients with both clinical N2 status and pathologic
multiple N2 nodes (n = 32) showed a 5-year survival of
5%; 76 patients with neither of the factors showed a 5-
year survival of 57% (P < .001; Fig 3).
Discussion
Suggestions that N2 disease actually consists of
many heterogeneous subgroups were confirmed by the
present study. Our results have shown that clinical N
status is one of the most significant prognostic factors,
on the basis of multivariable analysis. Tumor size, the
number of diseased N2 nodes, and curativity were also
selected as significant. We investigated the prognostic
factors among stage IIIA N2 lung cancer. The 5-year
survival of 173 patients classified as stage IIIA N2 dis-
ease was 30%. Multivariable analyses disclosed the
same 4 significant prognostic factors as those in over-
all patients. Among stage IIIA N2 disease, 97 patients
with clinical N0-1 who underwent complete resection
had a 5-year survival of 55%, although the other 76
patients had less than 10% survival (P < .001). Thus
even among stage IIIa N2 disease cases, which have
been dealt with in the same category, the prognosis of
resected N2 disease varies tremendously, and clinical
N2 still had a significant impact on the prognosis. 
Therefore, in interpreting a clinical trial on N2 disease,
it is important to know these prognostic factors; other-
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Table V. The 5-year survival in subgroups of surgical-
ly resected N2 non–small cell lung cancer with multi-
ple poor prognostic factors
5-Year 
Poor prognostic factors N survival (%) P value*
Clinical N2 status, tumor size larger than 2.0 cm, and 
incomplete resection
All factors 30 0 <.001†
1 or 2 factors 181 30
Neither factor 11 100
Clinical N2 status, multiple N2 nodes, and incomplete resection
All factors 27 0 <.001†
1 or 2 factors 167 25
Neither factor 28 76.1
Clinical N2 status and tumor size larger than 2.0 cm
Both factors 79 4 <.001†
Either factor 129 40
Neither factor 14 76
Clinical N2 status and multiple N2 nodes
Both factors 32 5 <.001†
Either factor 114 37
Neither factor 76 57
Tumor size larger than 2.0 cm and incomplete resection
Both factors 51 0 <.001†
Either factor 153 33
Neither factor 18 55
Multiple N2 nodes and incomplete resection
Both factors 47 0 <.001†
Either factor 140 25
Neither factor 35 65
Clinical N2 status and incomplete resection
Both factors 38 44 <.001†
Either factor 79 10
Neither factor 105 49
*P value in the log rank test.
†Considered to be statistically significant.
wise, even a phase III trial could allow misinterpretation
unless the number of enrolled patients was sufficiently
large. Sugarbaker and associates28 suggested that N2
status at resection predicts long-term outcome after
induction therapy for stage IIIA non–small cell lung
cancer. They stated that surgical restaging of mediasti-
nal nodes may be useful in patient treatment selection.
Furthermore, if patients show no diseased mediastinal
nodes after induction therapy, they could be a surgical
candidate because of their better prognosis. However,
they did not show clinical N status evaluation on the
basis of the CT scan for these patients, and it is possible
that these patients who showed no diseased mediastinal
nodes after induction therapy would have either clinical
N0-1 status on the basis of the CT evaluation or single
mediastinal nodal involvement, and completely
resectable. On the basis of the results, these patients
were among a favorable prognostic subgroup even
when they were treated with surgery alone: the good
prognosis could not be due to the induction strategy but
due to the patient selection conditions. Thus clinical tri-
als dealing with N2 disease should be designated con-
sidering these factors, and at least clinical N status
based on CT scan should always be described. Ideally,
these should be separate clinical trials on the clinical N2
population and the clinical N0-1 population, although
some previously reported clinical trials dealt with these
populations in the same trial.5,6,8-11
Our investigation of mediastinal nodal involvement
showed the prognostic value of the site of the involved
mediastinal lymph nodes. Inferior mediastinal nodes
(ie, 7-9 nodes, based on the Naruke map24) had a neg-
ative impact on prognosis, especially when the primary
tumor was located in a lower lobe. The reason for this
phenomenon remains unclear. Superior aortic nodes
(ie, 1-6) had a better outcome than N2 disease in other
locations, when the primary tumor was located in an
upper lobe. The prognosis of aortic nodes with positive
N2 status was excellent when the primary tumor was
located in the left upper lobe. In contrast, the prognosis
was poor when the primary tumor was located in a
lower lobe even if N2 disease was due to diseased aor-
tic nodes. The prognostic significance of the site of dis-
eased N2 nodes according to the tumor location still
remains controversial, and a further prospective study
is mandatory.
The prognostic significance of CT scans in resected
N2 lung cancer has been reported by Cybulsky and col-
leagues.16 Other authors3,16,18,19,29 also have reported
that clinical N2 status was a significant prognostic fac-
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Fig 3. Survival for patients with surgically resected N2 stage non–small cell lung cancer were compared based
on clinical N status and the number of diseased N2 nodes. A statistically significant difference was observed (log-
rank test, P < .001). cN0-1, Patients with clinical N0-1 status; cN2, patients with clinical N2 status.
tor in surgically resected N2 disease. However, the clin-
ical N2 status in these reports was mostly based on
plain x-ray films, except for the report by Cybulsky’s
group. Our result confirmed the prognostic significance
of CT-demonstrated nodal status in patients with N2
lung cancer in whom N2 status was confirmed by more
complete intraoperative nodal staging (eg, mediastinal
lymph node dissection). In contrast, some authors17,20
reported no significance of clinical N status, but the
number of investigated N2 patients were small in these
reports. Thus we considered that clinical N status is the
most significant prognostic factor in surgically resected
N2 non–small cell lung cancer.
As mentioned earlier, complete resection was one of
the most significant prognostic factors among resected
N2 disease. So we also investigated the prognostic fac-
tors among completely resected N2 lung cancer. In 167
such cases the 5-year survival was 36%. Multivariable
analysis revealed the following 4 significant prognostic
factors: clinical N2 status (P < .001; odds ratio [OR],
2.77; 95% confidence interval [CI], 1.78-4.31), the
presence of intrapulmonary metastasis (P = .027; OR,
1.99; 95% CI, 1.08-3.66), and the number of metastat-
ic N2 nodes (analyzed as a continuous variable: P <
.001; OR, 1.07; 95% CI, 1.03-1.12). It should be noted
that intrapulmonary metastasis was one of the most sig-
nificant prognostic factors among completely resected
N2 disease. Most intrapulmonary metastases in our
study were diagnosed pathologically and were diag-
nosed postoperatively. This means that postoperative
histologic examination of the whole resected lung spec-
imen should always be performed intensively to deter-
mine the presence of intrapulmonary metastases.
Although the International Union Against Cancer
TNM staging system has been revised, controversies
still remain.30 With regard to N2 disease, despite its het-
erogeneous population, significant prognostic factors
such as clinical N status, curativity, maximum tumor
dimension, or status of involved mediastinal lymph
nodes have rarely been taken into consideration. As a
result, the outcome of surgically resected N2 non–small
cell lung cancer population has varied tremendously.
This heterogeneity could cause erroneous conclusions
in clinical trials dealing with N2 disease.
We have shown the wide variety of outcome in surgi-
cally resected N2 disease. To perform a clinical trial
with multimodal treatment for N2 disease among a
homogeneous population with respect to prognosis,
clinical N status evaluated by CT scan should be one
criterion. Furthermore, completeness of surgical resec-
tion, the status of diseased N2 nodes, and also maxi-
mum tumor dimension should be mentioned in reports,
even in phase III trials. Stratification of surgically
resected N2 disease in this manner would help in accu-
rately interpreting important results of clinical trials
dealing with N2 disease.
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